Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Q3 2026 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, Aug 18, 2026
Slide 1: Conference call presentation 9M 2025/26
Conference call presentation 9M 2025/26 Making life easier Impact4: Setting the standard of care at scale Joshua | User, Ostomy Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: CEO's first 100 days: priorities for the next phase of Impact4
CEO's first 100 days: priorities for the next phase of Impact4 Increase focus on the US opportunity: Sustain the strength and 1 power of Chronic Care ~25% of Group sales come from the US today Increase focus on US 2 opportunity US Continence Care #1* ~30% market share (6-7bnDKK market) Accelerate Wo
Slide 4: Q3 2025/26 financial result
Q3 2025/26 financial result Organic EBIT growth ROIC growth in constant currencies 6% 5% * * 15% ** *before special items and in constant currencies Dorote | User, Continence Care **after tax and before special items. 4
Slide 5: 9M organic growth of 6% driven by Chronic Care and Interventional Urology
9M organic growth of 6% driven by Chronic Care and Interventional Urology 9M 2025/26 revenue by business area 9M 2025/26 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area mDKK growth area mDKK growth Ostomy
Slide 6: Reported revenue in 9M grew 3%, with 6% organic growth
Reported revenue in 9M grew 3%, with 6% organic growth and 3%-points negative impact from currencies 9M 2025/26 Revenue development (mDKK) 9M 2025/26 highlights • Reported revenue increased by DKK 568 million, or 3% vs. last year. • Organic growth was 6% or DKK 1,207 million, driven by: +568 mDKK •
Slide 7: EBIT margin of 26% in 9M: impact from currencies and Kerecis
EBIT margin of 26%1 in 9M: ~90 basis points negative impact from currencies and ~50 basis points negative impact from Kerecis 9M 2025/26 EBIT margin development before special items (%) 9M 2025/26 highlights • Gross margin of 67%, compared to 68% last year. • Negative impact from currencies (~90 bas
Slide 8: Strong FCF-to-sales ratio at 20% in 9M 2025/26 vs. 16% last year
Strong FCF-to-sales ratio at 20% in 9M 2025/26 vs. 16% last year1: positive working capital development and lower net financial items FCF development1 9M 2025/26 highlights • Adjusted FCF in 9M 2025/26 was DKK 4,232 million, or a 27% increase, 93 91 while Adjusted FCF-to-sales ratio was 20%, compare
Slide 9: Unchanged financial guidance for FY 2025/26
Unchanged financial guidance for FY 2025/26 Organic revenue growth 5-6% Reported revenue growth in DKK Around 3% EBIT growth* in constant currencies Around 5% ROIC** Around 15% Capex-to-sales ratio Around 5% Effective tax rate Around 22% *before special items. 9 **After tax, before special items
Slide 10: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding